Investigational New Drugs 1996-01-01

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.

P V Woolley, C J Schultz, G I Rodriguez, R A Gams, K W Rowe, M L Dadey, D D Von Hoff, J J McPhillips

Index: Invest. New Drugs 14(2) , 219-22, (1996)

Full Text: HTML

Abstract

We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. Toxicities were gastrointestinal (nausea, vomiting, diarrhea), fatigue and liver function abnormalities. These were severe and resulted in the removal of some patients from study. No consistent pattern of bone marrow suppression was seen. No tumor regressions occurred in 14 evaluable patients including 5 with no prior therapy. We conclude that ilmofosine is inactive in this tumor at this dose and schedule.